Document is current
Any future updates will be listed below
-
Authors
Athalye, Chinmayee
Bahena, Alejandra
Khandelwal, Pulkit
Emrani, Sheina
Trotman, Winifred
Levorse, Lisa M.
Khodakarami, Zahra
Ohm, Daniel T.
Teunissen-Bermeo, Eric
Capp, Noah
Sadaghiani, Shokufeh
Arezoumandan, Sanaz
Lim, Sydney A.
Prabhakaran, Karthik
Ittyerah, Ranjit
Robinson, John L.
Schuck, Theresa
Lee, Edward B.
Tisdall, M. Dylan
Das, Sandhitsu R.
Wolk, David A.
Irwin, David J.
Yushkevich, Paul A.
-
Funding
Funding for this research was provided by:
National Institutes of Health (P30-AG072979, RF1-AG056014)
- License Information
-
More Information
Article History
Received: 17 March 2025
Accepted: 5 May 2025
First Online: 28 May 2025
Declarations
:
: Where possible, pre-consent during life and, in all cases, next-of-kin consent at death was given. Imaging studies were approved by the Institutional Review Board at the University of Pennsylvania and were in accordance with the Declaration of Helsinki.
: All authors have reviewed the contents of the manuscript being submitted, approved of its contents, and validated the accuracy of the data and consented to publication.
: D.A.W. has served as a paid consultant to Eli Lilly, GE Healthcare, and Qynapse. He serves on a Data Safety and Monitoring Board for Functional Neuromodulation and GSK. He is a site investigator for a clinical trial sponsored by Biogen. D.J.I. is a member of the science advisory board of Denali Therapeutics. S.R.D. received consultation fees from Rancho Biosciences and Nia Therapeutics. The other authors have nothing to disclose.
